医学
心肌梗塞
2型糖尿病
不稳定型心绞痛
并发症
糖尿病
心绞痛
冲程(发动机)
回顾性队列研究
急诊医学
内科学
冠状动脉疾病
队列
机械工程
工程类
内分泌学
作者
JAY P. BAE,Vivian T. Thieu,MAUREEN J. LAGE,KRISTINA BOYE
出处
期刊:Diabetes
[American Diabetes Association]
日期:2023-06-20
卷期号:72 (Supplement_1)
摘要
Introduction: Cardiovascular (CV) disease is a major cause of morbidity and mortality for people with diabetes. This study examines the annual medical costs of newly identified CV complications for adults with type 2 diabetes (T2D). Methods: Optum’s de-identified Clinformatics® Data Mart data from 1/1/2015 - 6/30/2021 was used to examine a cohort of adults with T2D identified with a CV complication, with first such date identified as the index date. Descriptive statistics examined the direct medical costs (inpatient, emergency, and outpatient) associated with each complication in the 1st and 2nd year post index date. Complications included heart failure (HF), myocardial infarction (MI), stroke (STRK), hospitalization with a diagnosis of unstable angina (HUA), coronary revascularization (CR), and hypertension (HTN). Results: There were 167,046 patients with an average of 1.2 conditions of interest each. HTN (12.3%), STRK (12.1%), and HF (10.6%) were the most common complications. In the 1st year post index date, HUA, MI, and HF were the most expensive complications. In the 2nd year post index date, costs of each complication ranged from 1.7% (CR) to 65.0% (HTN) of 1st year costs (see Figure). Conclusion: Results illustrate the costs associated with CV-related complications for T2D and helps to quantify the economic burden that T2D imposes on U.S. healthcare systems. Disclosure J.P.Bae: None. V.Thieu: None. M.J.Lage: Consultant; Eli Lilly and Company. K.Boye: Employee; Eli Lilly and Company.
科研通智能强力驱动
Strongly Powered by AbleSci AI